Navigation Links
Antigen Express' AE37 Cancer Vaccine Featured in Scientific American
Date:9/21/2011

nting our scientific and clinical trial developments. Coinciding with Breast Cancer Awareness Month in October, the article also underscores our commitment to developing AE37 for the treatment of breast cancer and other indications," stated Dr. von Hofe.

About AE37

Antigen Express' novel Ii-Key Hybrid Preventive HER-2/neu Peptide Vaccine (AE37) is an "off-the-shelf" cancer immunotherapy product candidate that is easier and less costly to produce than comparable cell-based approaches.  AE37 is derived from a fragment of the HER2 oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian and other cancers. AE37 is positioned initially as an adjuvant therapy for at least 50% of breast cancer patients; i.e., those with low-to-intermediate levels of HER-2 expression who are not eligible for treatment with trastuzumab (Herceptin®).  Only 25% of breast cancer patients have HER-2 levels high enough to be eligible for Herceptin.

A controlled, randomized, and single-blinded Phase II clinical study of AE37 in HER-2 expressing breast cancer patients is currently underway to establish clinical efficacy.  The study endpoint is a reduction in cancer relapse after two years compared to patients not receiving AE37.  There are currently over 200 patients enrolled in the study with either node positive or high-risk node-negative breast cancer.  While positive preliminary results suggested that statistically definitive results could be obtained in 2012, the company opted to enroll an additional 100 patients in early 2011 to ensure sufficient patient numbers.  In particular, these additional patients are required to have low HER-2 expression levels such that they are not eligible for trastuzumab.  It is anticipated that a planned Phase 3 trial will be conducted in this specific patient population.

About Generex Biotechnology Corpo
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
2. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
3. Medicago succesfully expresses VLP antigen for A H1N1 strain
4. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
5. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
6. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
7. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
8. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
9. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
10. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
11. Generex Provides Update on Spinout of Antigen Express
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... 2014 This report covers ... in the life science industry. Continuous innovation ... reagents market towards remarkable growth. The stakeholders ... of life science reagents. , Brows full ... . , The global life science reagents ...
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a ... that are used solely in scientific experiments, is currently ... years in business, Maxim Peptide, which was created by ... a new and updated website that now features a ... has been updated with fascinating articles about peptide research, ...
(Date:7/11/2014)... 11, 2014 , Not for release, ... or from any jurisdiction where to do so would constitute ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ...  Shire confirms it has held a meeting with representatives of ... without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... , July 11, 2014 Research ... "International Transfection Technology Market - Global Industry Analysis, Size, ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... introduce nucleic acids (either DNA or RNA) into cells. ... mutation of cancer cells and protein metabolism by affecting ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2
... 7 When leading contract research,organization Pharm-Olam International (POI, ... voice-over Internet protocol (VoIP),system that would better serve the ... catastrophic., POI initially selected a local vendor to ... immediately clear the solution was a bigger problem,than the ...
... LifeQuest World Corporation,(OTC Bulletin Board: LQWC) is pleased ... ImmunXT, their Immune System enhancement supplement, has,been released ... of March 2008.,ImmunXT has been proclaimed as "the ... (US Patent #7,205,284 B2),is a bio-active Micro-algae Complex ...
... Eastern Time -, SOUTH SAN FRANCISCO, Calif., May ... biopharmaceutical company focused,on oncology, today reported on its corporate ... 31, 2008., "During the first quarter, we made ... data to demonstrate the potential of,picoplatin as a new ...
Cached Biology Technology:Pharm-Olam Finds VoIP Solution in Taridium LLC 2LifeQuest World Launches Immune System Boosting Supplement to the North American Market 2Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 2Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 3Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 4Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 5Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 6Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 7Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 8Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 9
(Date:7/11/2014)... A new report from the Wildlife Conservation Society ... only help economically valuable species such as lobster, ... also help re-colonize nearby reef areas. , The ... a systematic review of research literature from no-take ... by Dr. Craig Dahlgren, a recognized expert in ...
(Date:7/11/2014)... at the Department of Energy,s Oak Ridge National ... by R&D Magazine in recognition of the year,s ... the tremendous value of our National Labs," said ... at the National Labs continues to help our ... scientific and technological innovations necessary to remain globally ...
(Date:7/11/2014)... eastern New South Wales, Australia when NASA,s Aqua satellite ... on July 11 (12:35 p.m. local time/11:35 p.m. EDT ... South Wales (NSW), the Moderate Resolution Imaging Spectroradiometer (MODIS) ... and spotted smoke (light brown) from various fires. Actively ... in red. , The New South Wales, Australia Government ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... and treatment of breast cancer, the disease remains a ... technology under investigation at the Biodesign Institute at Arizona ... cell nuclear structure, the molecular biosignature of cancer, thus ... detection of the disease. The team, led by ...
... half years since Adam Bogdanove, professor at Iowa State University ... Matthew Moscou, a former graduate student in that department, discovered ... and bind specific sequences in plant genomes, researchers worldwide have ... was first shown that the proteins can be fused to ...
... Scientists have uncovered a lot about the Earth,s greatest ... rapid climate change wiped out nearly all marine species and ... a new culprit likely involved in the annihilation: an influx ... looked to see if mercury was a potential culprit. This ...
Cached Biology News:Cell-CT: A new dimension in breast cancer research 2Cell-CT: A new dimension in breast cancer research 3Cell-CT: A new dimension in breast cancer research 4ISU scientist helps find structure of gene-editing protein named Method of the Year 2Earth's massive extinction: The story gets worse 2
... PP2A1, purified Formulation: 50mM Tris-HCl, ... Brij-35, 0.2mM PMSF, 1mM benzamidine, ... Properites: PP2A1 (Protein Phosphatase 2A1) ... ammonium sulfate precipitation, QSepharose,amino-hexyl agarose, ...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
...
... Anti-HMGN2/HMG-17 Immunogen : Recombinant ... pH7.4, 5mg/ml BSA, 0.15M NaCl, ... addition of glycerol to 30% ... immunoblot on acid extracts of ...
Biology Products: